Drugs / Valsartan+Sacubitril
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06655480 | Mar 2025 → Dec 2027 expected | intrinsic cardiomyopathy, symptomatic heart failure | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Valsartan+Sacubitril | “Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet” NCT06655480 ↗ |